Medbanks
思 派 健 康 科 技

Sipai Health Technology Co., Ltd.
思派健康科技有限公司

(A company incorporated in the Cayman Islands with limited liability)
(Stock Code: 0314)

VOLUNTARY ANNOUNCEMENT INCREASE IN SHAREHOLDING IN THE COMPANY BY EXECUTIVE DIRECTORS; AND ON-MARKET SHARE REPURCHASES BY THE COMPANY

This announcement is made by Sipai Health Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

INCREASE IN SHAREHOLDING IN THE COMPANY BY EXECUTIVE DIRECTORS

The board (the "**Board**") of directors (the "**Director(s)**") of the Company has been informed by our executive directors, Mr. MA Xuguang and Mr. LI Ji, that based on the firm confidence in the Company's future development prospects and recognition of its long-term investment value, Mr. MA Xuguang, through Lucky Seven Healthcare Co., Ltd., and Mr. LI Ji, through Spire-succession Limited, have each acquired 3,640,000 ordinary shares of the Company (the "**Shares**") (an aggregate of 7,280,000 Shares of the Company, representing approximately 1.00% of the total number of issued Shares (excluding treasury shares) as at the date of this announcement) on July 15, 2026, at a price of HK$1.40 per Share with their respective own funds.

Immediately following the increase in shareholding and as at the date of this announcement, Mr. MA Xuguang holds 60,640,000 Shares, representing approximately 8.34% of the total number of issued Shares (excluding treasury shares). Mr. LI Ji holds 43,640,000 Shares, representing approximately 6.00% of the total number of issued Shares (excluding treasury shares).

ON-MARKET SHARE REPURCHASES BY THE COMPANY

The Company is pleased to also announce that between January 1, 2026 and the date of this announcement, a total of 22,400,200 shares of the Company have been repurchased (the "**Share Repurchases**"), for a total consideration of approximately HK$44,690,400, further demonstrating the Company's confidence in its long term development and value.

The Board believes that the Share Repurchases reflect the management's firm confidence in the long-term value of the enterprise and is conducive to enhancing the Group's capital market value and its ability to deliver returns to shareholders of the Company (the "**Shareholders**"). The Share Repurchases are in the interests of the Company and its Shareholders as a whole.

The Board conducted the Share Repurchases under the general mandate to repurchase the Shares of the Company ("**Repurchase Mandate**") granted by resolution of the Shareholders passed in the annual general meeting of the Company held on June 18, 2026 (the "**AGM**") and the preceding repurchase mandate granted in the annual general meeting of the Company held on June 20, 2025. Pursuant to the Repurchase Mandate, the Company is allowed to repurchase up to 72,989,391 shares being 10% of the number of Shares in issue as at the date of the AGM. Based on the public information available to the Company and as far as the Board is aware, following the increase in Mr. MA Xuguang and Mr. LI Ji's shareholding in the Company and the Share Repurchases, and as at the date of this announcement, the Company has continued to maintain sufficient public float of the issued Shares in compliance with Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Shareholders and potential investors of the Company are advised that the repurchase of Shares is subject to the sole discretion of the Directors based on the market conditions and that no assurance can be given as to the timing, quantity or price of any repurchase. As such, Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Sipai Health Technology Co., Ltd.
Ma Xuguang
Chairman of the Board and Executive Director

Hong Kong, July 15, 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. MA Xuguang and Mr. LI Ji as executive directors, Mr. YAO Leiwen as non-executive director, Mr. FAN Xin, Mr. HE Haijian and Ms. HUANG Bei as independent non-executive directors.